Science

CIMAP’s Herbal products may boost immunity to avoid infection

India Science Wire New Delhi | Updated on April 25, 2020 Published on April 25, 2020

Researchers at Central Institute of Medicinal and Aromatic Plants (CIMAP), Lucknow, has developed scientifically proven two herbal products, which can boost the immunity of the persons as well as help in alleviating the dry cough symptom generally associated with the coronavirus infection.

CIMAP, a constituent laboratory of the Council of Scientific and Industrial Research (CSIR), has decided to transfer the technology of its herbal products ‘CIM-Paushak’ and ‘Herbal Cough Syrup’ to the entrepreneurs and start-up companies. These two products were found to be effective in boosting the immunity of a person. Twelve valuable herbs including Puranva, Ashwagandha, Mulethi, Harad, Baheda and Sataver compounds have been used in both these products. 

“The Institute would provide its pilot facility for manufacturing these herbal products - ‘CIM-Paushak’ and ‘Herbal Cough Syrup’ - to entrepreneurs and start-ups after signing of the MoU and transfer of technology”, said Dr. Prabodh  K. Trivedi, Director, CIMAP. This pilot plant is equipped with state-of-the-art facilities and a quality control cell. 

“Scientific studies have shown that ‘CIM-Puashak’ has performed better than other available immunity booster products in the market. It has also been found to be cheap, safe and effective in the animal trials conducted in the institute”, said Dr. D.N. Mani, lead researcher of the study. Herbal Cough Syrup is developed based on latest guidelines of the AYUSH ministry, and it has been prepared on the basis of the  ‘Tridosha’ principle of Ayurveda, explained Dr. Mani. 

According to health experts, coronavirus reduces the immune response of the infected person and it has been observed that this pandemic has mostly affected people with low immune system. The experts feel that improvement of the immune system helps in reducing the effects of the infection and also fight the COVID-19 disease.

Umashankar Mishra

Twitter handle : @usm_1984

Published on April 25, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Sincerely,

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.